Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist

January 2, 2014

TSX Exchange Symbol: RVX

CALGARY, Jan. 2, 2014 /PRNewswire/ – Resverlogix Corp. (TSX: RVX) today
announced that a publication titled “RVX-208, an Inducer of ApoA-I in
Humans, Is a BET Bromodomain Antagonist” was published on December 31(st) 2013 in the international, peer-reviewed, open-access online
publication PLOS ONE Journal. The publication was authored by
Resverlogix staff in combination with collaborators from Xtal
Biostructures Inc. in Maryland USA.

This publication is the third recent publication discussing the unique
attributes of RVX-208. In October 2013 the Structural Genomics
Consortium, in conjunction with a group of University of Oxford UK
scientists, published a work titled “RVX-208, an inhibitor of BET
transcriptional regulators with selectivity for the second
bromodomain”. This paper was a peer reviewed publication in by the
Proceedings of the National Academy of Sciences of the United States of

“The Structural Genome – Oxford paper was viewed by us as an extremely
important publication as it confirmed by an external group for the
first time that RVX-208 was the first known selective BET inhibitor
thus highlighting Resverlogix’ technological lead in the bromodomain
space,” said Donald J. McCaffrey, President & CEO of Resverlogix.

In August 2013 a third publication in the Cell Journal, titled “BET
Bromodomains Mediate Transcriptional Pause Release in Heart Failure”,
used RVX-208 as one of the BET inhibitors that confirmed the potential
for BET inhibitors as therapeutic targets in heart failure. The authors
of this publication were primarily from various divisions of Harvard
Medical School.

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque via
reverse cholesterol transport (RCT), the natural process through which
atherosclerotic plaque is transported out of the arteries and removed
from the body by the liver. RVX-208 increases production of
Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
These newly produced, functional HDL particles are flat and empty and
can efficiently remove plaque and stabilize or reverse atherosclerotic
disease. Post-hoc analysis of recent clinical trials data showed that
RVX-208 significantly reduces coronary atherosclerosis and major
adverse cardiac events in patients with CVD who have a low level of HDL
and elevated CRP, a population with unmet medical need. ApoA-I may also
exert beneficial effects in Alzheimer’s disease and Diabetes Mellitus.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix’s common shares trade on the Toronto Stock Exchange
(TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

Resverlogix IR App

This app gives Resverlogix investors mobile access to the latest stock
data, news, and SEC Filings. It also provides proprietary company
content including presentations, conference calls, videos, fact sheets,
annual reports and other qualitative company information. Investors are
able to receive ‘push’ notifications when new content is added to the
IR App such as add events to calendars, share content and as well as
download files for offline viewing.

To download the Resverlogix IR App, please visit your app store.

Apple Products (iPhone, iPad, and iPod’s)https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=730718904&mt=8

Android Products (Google Play, Tablets and Smartphones)https://play.google.com/store/apps/details?id=com.theirapp.resverlogix

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words “believes”, “anticipates”, “plans”, “intends”,
“will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk
factors including those discussed in our Annual Information Form and
most recent MD&A which are incorporated herein by reference and are
available through SEDAR at www.sedar.com. The forward-looking
statements contained in this news release are expressly qualified by
this cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.

    Company Contacts:

    Donald J. McCaffrey                                                    Kenneth Lebioda
    President and CEO                                                      SVP Business & Corporate Development
    Resverlogix Corp.                                                      Resverlogix Corp.
    Phone: 403-254-9252                                                    Phone: 403-254-9252
    Email:                                                                 Email:
    don@resverlogix.com           ken@resverlogix.com

SOURCE Resverlogix Corp.

Source: PR Newswire

comments powered by Disqus